Eupraxia Pharmaceuticals Reports Strong Tissue Health Improvements in Ongoing RESOLVE EoE Trial

Eupraxia Pharmaceuticals Inc. has released positive new data from its ongoing Phase 1b/2a RESOLVE clinical trial evaluating EP‑104GI as a potential treatment for eosinophilic esophagitis (EoE), showing encouraging improvements in esophageal tissue health. At 12 weeks, patients receiving the highest dose of EP‑104GI demonstrated the most substantial gains to date, with near‑complete normalization of tissue health based on histological scoring. Improvements in tissue health were sustained through 36 weeks in patients receiving lower doses, and clinical remission was achieved by 8 weeks and maintained through 52 weeks in most patients treated over at least 60 % of the esophagus. EP‑104GI was well tolerated across all dose levels, with over 200 patient‑months of follow‑up, no reported serious adverse events, and no cases of oral candidiasis. Eupraxia’s CEO Dr. James A. Helliwell highlighted that these tissue improvements were accompanied by symptom relief and maintained long‑term after a single administration, underscoring EP‑104GI’s potential as a once‑yearly therapy that could improve the current standard of care for EoE. #EupraxiaPharma #EosinophilicEsophagitis #RESOLVEtrial #EP104GI #SlimScan #GrowthStocks #CANSLIM